Trial Profile
A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms N3 Study
- 20 Nov 2020 Status changed from not yet recruiting to withdrawn prior to enrolment due to withdrawal of financial support from funder.
- 01 May 2020 Planned End Date changed from 1 Jan 2023 to 1 Jul 2023.
- 01 May 2020 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2023.